Today Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) Reported Increase in Shorted Shares

June 13, 2018 - By Clifton Ray

VBI Vaccines Inc. (NASDAQ:VBIV) Logo

The stock of Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) registered an increase of 11.31% in short interest. VBIV’s total short interest was 820,900 shares in June as published by FINRA. Its up 11.31% from 737,500 shares, reported previously. With 131,400 shares average volume, it will take short sellers 6 days to cover their VBIV’s short positions. The short interest to Vbi Vaccines Inc – Ordinary Shares’s float is 2.14%.

The stock increased 5.56% or $0.202 during the last trading session, reaching $3.842. About 673,204 shares traded or 283.58% up from the average. VBI Vaccines Inc. (NASDAQ:VBIV) has declined 26.86% since June 13, 2017 and is downtrending. It has underperformed by 39.43% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $246.75 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

More news for VBI Vaccines Inc. (NASDAQ:VBIV) were recently published by:, which released: “VBI Vaccines Announces Results of Annual General Meeting” on May 25, 2018.‘s article titled: “Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress” and published on May 22, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: